Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data

(2021) Antonia M. Joussen et al.   EYE

Non-adherence or non-persistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review

(2020) Mali Okada et al.   OPHTHALMOLOGY

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

(2020) Jayashree Sahni et al.   JAMA Ophthalmology

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

(2020) Arshad M. Khanani et al.   JAMA Ophthalmology

THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES

(2020) Jeffrey S. Heier et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration

(2019) Mark C. Gillies et al.   JAMA Ophthalmology

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

(2019) Pravin U. Dugel et al.   OPHTHALMOLOGY

Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study

(2019) Michèle Augsburger et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration

(2018) Rufino Silva et al.   OPHTHALMOLOGY

Age-related macular degeneration

(2018) Paul Mitchell et al.   LANCET

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

(2016) Jörg T Regula et al.   EMBO Molecular Medicine

Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study

(2015) Jonathan L. Prenner et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration

(2015) Charles C. Wykoff et al.   OPHTHALMOLOGY

Molecular pathogenesis of retinal and choroidal vascular diseases

(2015) Peter A. Campochiaro   PROGRESS IN RETINAL AND EYE RESEARCH

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration

(2014) Frank G Holz et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration

(2013) Brandon G. Busbee et al.   OPHTHALMOLOGY

HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

(2012) Michael A. Singer et al.   OPHTHALMOLOGY

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

(2012) Jeffrey S. Heier et al.   OPHTHALMOLOGY

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

(2011) W. Schaefer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

(2008) Carl D. Regillo et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY